ARVN — ARVINAS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1655759 ·
Last close
$9.34
Market Cap
$610.71M
52W High
$9.69
52W Low
$6.97
ADV30
805,249
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 249,700,000 | — | 164,100,000 | 169,400,000 | 675,100,000 | 94,300,000 | 113,000,000 |
| Mar 2026 | 15,600,000 | — | -63,800,000 | -57,600,000 | 647,500,000 | 87,300,000 | 260,700,000 |
| Dec 2025 | 9,500,000 | — | -74,600,000 | -67,400,000 | 717,900,000 | 142,900,000 | 284,100,000 |
| Sep 2025 | 41,900,000 | — | -43,800,000 | -35,100,000 | 844,300,000 | 101,500,000 | 279,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-207,000,000
Investing CF
$277,900,000
Financing CF
$-91,500,000
CapEx
$-1,800,000
Dividends Paid
—
Buybacks
$-74,100,000
EPS Diluted TTM
$0.10
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,500,600,000
Inventory
—
Receivables
$54,300,000
ST Investments
$473,600,000
EBIT TTM
$-18,100,000
Pretax Income TTM
$10,100,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$316,700,000
EBITDA
$-9,900,000
Free Cash Flow
$-94,500,000
Enterprise Value
$52,441,680
Total Cash
$567,900,032
Total Debt
$8,000,000
Shares Out
65,386,191
Trailing EPS
$0.26
Book Value
$8.61
ROE
1.6%
ROA
-1.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 262,600,000 | -118,500,000 | -80,800,000 | 717,900,000 | 284,100,000 | — | -273,800,000 |
| Dec 2024 | 263,400,000 | -250,200,000 | -198,900,000 | 1,091,400,000 | 529,800,000 | — | -259,300,000 |
| Dec 2023 | 78,500,000 | -401,500,000 | -367,300,000 | 1,304,600,000 | 644,600,000 | — | -347,800,000 |
| Dec 2022 | 131,400,000 | -263,200,000 | -282,500,000 | 1,268,800,000 | 703,900,000 | — | -273,500,000 |
TTM Snapshot
Revenues TTM
$153,600,000
NetIncome TTM
$-212,200,000
OpCashFlow TTM
$0
Assets (Latest)
$1,091,400,000
Forward EPS
$-3.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALT | Altimmune, Inc. | $604.95M | $3.11 | — |
| AQST | Aquestive Therapeutics, Inc. | $602.46M | $4.80 | — |
| VSTM | Verastem, Inc. | $621.27M | $6.86 | — |
| SGMT | Sagimet Biosciences Inc. | $628.85M | $10.21 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $630.33M | $16.97 | — |
News headlines (Yahoo Finance, 1h cache)
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
2026-08-11 18:05 · Yahoo
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
2026-08-06 16:00 · Yahoo
Arvinas Q2 Earnings Call Highlights
2026-08-04 14:04 · Yahoo
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-04 11:00 · Yahoo
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
2026-06-05 16:10 · Yahoo
Arvinas to Present at Jefferies Global Healthcare Conference
2026-05-29 20:01 · Yahoo
Arvinas Employees Give Back During Company-wide Impact Day
2026-05-18 14:30 · Yahoo
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
2026-05-16 13:40 · Yahoo
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-14 12:48 · Yahoo
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
2026-05-13 17:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.